Original paper

European Archives of Psychiatry and Clinical Neuroscience

, Volume 251, Issue 2, pp 57-59

First online:

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report

  • A. SuzukiAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , T. KondoAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , K. MiharaAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , N. Yasui-FurukoriAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , K. OtaniAffiliated withDepartment of Neuropsychiatry, Yamagata University School of Medicine, Yamagata, Japan
  • , H. FurukoriAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , S. KanekoAffiliated withDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • , Y. InoueAffiliated withPharmaceutical Technology Center, Yoshitomi Pharmaceutical Industries Ltd., Fukuoka, Japan

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The relationship between TaqI A dopamine D2 receptor (DRD 2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6–18 mg/day for 3 weeks. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The TaqI A genotypes were determined with the PCR method. There was no significant difference in the percentage improvement of total BPRS or 5-subgrouped symptoms (positive, negative, anxiety-depression, excitement and cognitive symptoms) after the 3-week treatment between the patients with A1 alleles (n=18) and those with no A1 allele (n=12). Although the present study is preliminary, it is suggested that the TaqI A DRD 2 polymorphism is not associated with therapeutic response to bromperidol in schizophrenic patients.

Key words Bromperidol Schizophrenia TaqI A DRD2 polymorphism Therapeutic response